Key Points Non-GAAP EPS was $0.65 for Q2 2025, surpassing estimates by 54.8%. Adjusted EBITDA reached a record $4.64 billion in Q2 2025, This compares with $4.34 billion in the same period of 2024.

Key Points Earnings per share (Non-GAAP) were $0.94 in Q2 2025 beating the analyst estimate by 9.3% (non-GAAP) and the company exceeded its non-GAAP EPS outlook by $0.08. Net sales (GAAP) reached ...

Explore IDACORP's Q2 2025 earnings insights, highlighting EPS guidance increase, customer growth, key investments, and resource planning amid ...

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

Second Quarter 2025 Results Key Financial Results Revenue: US$1.49b (up 7.6% from 2Q 2024).

Second Quarter 2025 Results Key Financial Results Revenue: US$750.2m (up 42% from 2Q ...

Q2 2025 Management View Christopher H. Peterson, President and CEO, highlighted that “Newell Brands demonstrated tremendous ...

Q2 2025 Management View Karl G. Glassman, President, CEO & Chairman, introduced Steve West as the new Vice President of ...

This article breaks down a key moment from The Gilded Age Season 3, Episode 6. Proceed at your own risk. Oscar van Rhijn will ...

If a company’s most recent quarterly EPS is $0.12, and its EPS in the same quarter last year was $0.09, then it has a quarterly year-over-year EPS growth rate of 33%.

EPS is a key component of the price-to-earnings (P/E) valuation ratio. Divide the share price by EPS, and you get a multiple that tells you how much you pay for $1 of the company’s profit. In ...